News | March 19, 2026
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
The initial consideration for the transaction is US$ 12 million
The company announced positive topline data from the Phase 3 ADorable-1 trial
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The conflict is also triggering a widening public health emergency
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Subscribe To Our Newsletter & Stay Updated
